Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a significant decline in short interest in September. As of September 15th, there was short interest totaling 21,975 shares, a decline of 44.1% from the August 31st total of 39,331 shares. Currently, 3.5% of the company’s stock are short sold. Based on an average daily volume of 27,758 shares, the days-to-cover ratio is currently 0.8 days.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on SHPH shares. Wall Street Zen raised shares of Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, July 4th. Weiss Ratings cut Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Insider Activity at Shuttle Pharmaceuticals

In related news, major shareholder Financial Lp Hrt purchased 8,266 shares of Shuttle Pharmaceuticals stock in a transaction that occurred on Thursday, July 9th. The shares were purchased at an average cost of $3.38 per share, with a total value of $27,939.08. Following the transaction, the insider owned 60,540 shares of the company’s stock, valued at approximately $204,625.20. The trade was a 15.81% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders bought 16,848 shares of company stock worth $58,005 and sold 38,133 shares worth $132,128. Insiders own 0.36% of the company’s stock.

Shuttle Pharmaceuticals Price Performance

Shares of SHPH traded up $0.12 during trading hours on Wednesday, reaching $4.04. 31,235 shares of the company’s stock traded hands, compared to its average volume of 847,586. The firm has a market capitalization of $2.57 million, a price-to-earnings ratio of -0.22 and a beta of 0.21. The business’s fifty day simple moving average is $3.64 and its two-hundred day simple moving average is $5.37. Shuttle Pharmaceuticals has a twelve month low of $2.58 and a twelve month high of $55.90.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc is a clinical-stage specialty pharmaceutical company focused on developing therapies designed to improve the effectiveness of radiation treatment for cancer patients. The company’s research centers on radiosensitizers, which are intended to make tumor cells more sensitive to radiation while helping preserve surrounding healthy tissue.

Shuttle’s lead product candidate is ropidoxuridine, an orally administered investigational therapy being developed for use in combination with radiation therapy.